Clinical trials: Eye
Dry Eye Syndromes
Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease
This study will evaluate a new ophthalmic formulation of cyclosporine (Restasis® X) in patients with moderate to severe dry eye disease in two stages. Up to 3 doses will be studied in Stage 2 based on results from Stage 1.
- Trial name
- NCT02013791
- Testing
- Vehicle, Cyclosporine New Ophthalmic Formulation
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Allergan
Cataract, Corneal Astigmatism
Evaluation of the Rotational Stability of the Tecnis Toric II IOL
This is a prospective, multicenter, single-arm, open-label clinical study of the commercially available TECNIS Toric II IOL. The study will be conducted in up to 192 subjects needing unilateral or bilateral cataract surgery in up…
- Trial name
- STEELE (NCT04327518)
- Testing
- TECNIS® Toric II
- Where
- 7 sites in United States
- Volunteers
- 125 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.
Cataract, After Cataract
Autonomous Telephone Follow-up After Cataract Surgery
This project will apply AI technology to meet the gap between increasing demand and limited capacity of high- volume healthcare services.
- Trial name
- NCT05213390
- Testing
- Dora
- Where
- 2 sites in United Kingdom
- Volunteers
- 225 people
- Sponsor
- University of Plymouth
Myopia
A Study to Evaluate the Product Feasibility of Two New Silicone Hydrogel Contact Lenses
The objective of this study is to determine the clinical feasibility and to evaluate the product performance of two RD2135-01 investigational soft contact lenses (Test 1 and Test 2) developed by Bausch + Lomb.
- Trial name
- NCT01583868
- Testing
- B&L RD2135-01 lens C, B&L RD2135-01 lens D, PureVision2
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- Bausch & Lomb Incorporated
Supranuclear Palsy, Progressive
Study of BIIB092 in Participants With Progressive Supranuclear Palsy
The Primary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) at Week 52 and to assess the safety and tolerability of…
- Trial name
- PASSPORT (NCT03068468)
- Testing
- BIIB092
- Where
- 86 sites in United States, Australia and 11 more
- Volunteers
- 490 people
- Sponsor
- Biogen
Pediatric Glaucoma, Elevated IOP in Pediatric Patients
Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of Travoprost 0.004% POLYQUAD (PQ) ophthalmic solution compared to Timolol ophthalmic solution (0.5% or 0.25%) in pediatric glaucoma…
- Conditions
- Pediatric Glaucoma, Elevated IOP in Pediatric Patients, Ocular Hypertension in Pediatric Patients
- Trial name
- NCT01652664
- Testing
- Travoprost 0.004% PQ ophthalmic solution, Timolol, 0.5% or 0.25% ophthalmic solution, Travoprost Vehicle
- Volunteers
- 184 people
- Sponsor
- Alcon Research
Presbyopia
Evaluation of an Investigational Multifocal Lens
The purpose of this study is to test the performance of an investigational multifocal test soft contact lens.
- Trial name
- NCT02223754
- Testing
- lotrafilcon B, etafilcon A
- Where
- 20 sites in United States
- Volunteers
- 371 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Retinal Vein Occlusion
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
To determine the efficacy of vascular endothelial growth factor (VEGF) Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion
- Trial name
- GALILEO (NCT01012973)
- Testing
- Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
- Where
- 73 sites in Australia, Austria and 8 more
- Volunteers
- 177 people
- Sponsor
- Bayer
Neuromyelitis Optica
C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation
The overall objective is to evaluate the tolerability/safety and preliminary efficacy of CINRYZE® (C1 esterase inhibitor [human]) as add-on therapy for treatment of acute optic neuritis and/or transverse myelitis in NMO and…
- Trial name
- NCT01759602
- Testing
- C1-esterase inhibitor (Cinryze)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Michael Levy
Retinitis Pigmentosa
Argus® II Retinal Stimulation System Feasibility Protocol
Investigational Phase of the Study: The objective of this feasibility study is to evaluate the safety and utility of the Argus II Retinal Stimulation System in providing visual function to blind subjects with retinitis…
- Trial name
- NCT00407602
- Testing
- Implant of Argus II Retinal Prosthesis
- Where
- 12 sites in United States, France and 3 more
- Volunteers
- 30 people
- Sponsor
- Second Sight Medical Products
Central Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
Provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to CRVO
- Trial name
- Camellia (NCT01976312)
- Testing
- Ranibizumab 0.5 mg
- Where
- 34 sites in China, Hong Kong and 5 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Conjunctivitis
A Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis
To engage in a multi-center, prospective, masked clinical trial to investigate a non-invasive, rapid diagnostic test, the RPS Adeno Detector IV's ability to detect the presence of the adenovirus (ADV) antigen in cases of acute…
- Trial name
- NCT00921895
- Testing
- RPS Adeno Detector IV
- Where
- 8 sites in United States
- Volunteers
- 128 people
- Sponsor
- Rapid Pathogen Screening
Glaucoma
COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)
A study to evaluate the effect of the 12-week treatment with timolol/dorzolamide combination eyedrops (COSOPT) on decrease in intraocular pressure (IOP) at 2 hours after the study drug administration
- Trial name
- NCT00832377
- Testing
- timolol/dorzolamide combination
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Sleep
SleepSure: A Trial to Assess the Effects of Eye Masks and Earplugs on Hospital Inpatient Sleep
The aim of this study is to determine whether routinely providing patients admitted to hospital with two devices to help sleep - ear plugs, and an eyeshade - leads to patients having a better quality of sleep and/or longer, more…
- Trial name
- NCT02732912
- Testing
- Ear plugs, Eye Mask, Zopiclone
- Volunteers
- 206 people
- Sponsor
- Oxford University Hospitals NHS Trust
Epiphora, Dacryocystorhinostomy
SLlt Stent II Lacrimal Stent for the Treatment of Nasolacrimal Duct Obstruction
This project aims to test whether a newly designed lacrimal stent - the SlitStent - when placed into the lacrimal system in the standard fashion following a DCR surgery, will provide good symptomatic relief for epiphora and be…
- Trial name
- SLINDO (NCT03705000)
- Testing
- Slit Stent II, BIKA for DCR
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Thomas Gardner
Dry Eye
Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
Can Lyrica (Pregabalin) help prevent severe Dry Eye post LASIK surgery?
- Trial name
- NCT02701764
- Testing
- Pregabalin
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Miami
Glaucoma, Ocular Hypertension
Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution
- Trial name
- NCT06394973
- Testing
- T4090 0.2%, T4090 0.3%, Rhopressa®
- Where
- 24 sites in United States
- Volunteers
- 161 people
- Sponsor
- Laboratoires Thea
Open-angle Glaucoma, Ocular Hypertension
A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Treatment of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for…
- Trial name
- NCT03216902
- Testing
- Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution
- Where
- 17 sites in United States, Japan
- Volunteers
- 241 people
- Sponsor
- Santen Inc.
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00084656
- Testing
- ipilimumab, Tyrosinase/gp100/MART-1 Peptides
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bristol-Myers Squibb
Anesthesia, Local
A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population
A Phase 3, randomized, active-controlled, study in pediatric subjects. It is designed to evaluate the safety and anesthetic efficacy of one dose of AG-920 ophthalmic solution compared to Proparacaine Hydrochloride Ophthalmic…
- Trial name
- NCT05325853
- Testing
- AG-920, Proparacaine Ophthalmic
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- American Genomics, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.